Response to "Warning flags for erythropoiesis-stimulating agents and cancer-associated anemia" [1]

Oncologist

Volumn 12, Issue 8, 2007, Pages 1031-1032

  Littlewood, Timothy J ^a  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CONTINUOUS ERYTHROPOIESIS RECEPTOR ACTIVATOR; ERYTHROPOIETIN; HEMOGLOBIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PLACEBO;

ANEMIA; BLOOD TRANSFUSION; BREAST CANCER; CANCER RECURRENCE; CANCER SURVIVAL; CIGARETTE SMOKING; CLINICAL TRIAL; DISEASE ASSOCIATION; HEAD AND NECK CANCER; HUMAN; LETTER; LIFE EXPECTANCY; LUNG NON SMALL CELL CANCER; PERIOPERATIVE PERIOD; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; TREATMENT OUTCOME;

ANEMIA; ERYTHROPOIESIS; HEMATINICS; HUMANS; NEOPLASMS;

EID: 34548406042     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.12-8-1031     Document Type: Letter

References (11)

1. Lappin TR, Maxwell AP, Johnston PG. Warning flags for erythropoiesisstimulating agents and cancer-associated anemia. The Oncologist 2007;12:362-365.
2. Littlewood TJ, Bajetta E, Nortier JW et al. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: Results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2001;19:2865-2874.
3. Amato A, Pescatori M. Perioperative blood transfusions for the recurrence of colorectal cancer. Cochrane Database Syst Rev 2006;(1):CD005033.
4. Henke M, Laszig R, Rube C et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: Randomised, double-blind, placebo-controlled trial. Lancet 2003;362:1225-1260.
5. Leyland-Jones B; BEST Investigators and Study Group. Breast cancer trial with erythropoietin terminated unexpectedly. Lancet Oncol 2003;4:459-460.
6. Wright JR, Ung YC, Julian JA et al. Randomized, double-blind, placebocontrolled trial of erythropoietin in non-small-cell lung cancer and disease-related anemia. J Clin Oncol 2007;25:1027-1032.
7. Goldberg P. Study finds more deaths on Aranesp arm in cancer anemia study: No benefit seen. Cancer Lett 2007;33:1.
8. Hoffmann-La Roche Limited. Recruitment Temporarily Suspended Into C.E.R.A. Phase II Oncology Trial, Roche Media News, February 23, 2007. Available at http://www.roche.com/med-cor-2007- 02-23c. Accessed August 1, 2007.
9. Henke M, Mattern D, Pepe M et al. Do erythropoietin receptors on cancer cells explain unexpected clinical findings? J Clin Oncol 2006;24:4708-4713.
10. Ragione FD, Cucciolla V, Borriello A et al. Erythropoietin receptors on cancer cells: A still open question. J Clin Oncol 2007;25:1812.
11. Bohlius J, Wilson J, Seidenfeld J et al. Recombinant human erythropoietins and cancer patients: Updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst 2006;98:708-714.